Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Assets (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Current Assets for 7 consecutive years, with $606.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 2.03% to $606.8 million in Q4 2025 year-over-year; TTM through Nov 2025 was $606.8 million, a 2.03% decrease, with the full-year FY2025 number at $606.8 million, down 2.03% from a year prior.
  • Current Assets was $606.8 million for Q4 2025 at Nurix Therapeutics, up from $440.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $619.4 million in Q4 2024 to a low of $251.0 million in Q1 2024.
  • A 5-year average of $384.1 million and a median of $336.7 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: fell 24.49% in 2023, then skyrocketed 124.61% in 2025.
  • Nurix Therapeutics' Current Assets stood at $311.1 million in 2021, then increased by 2.36% to $318.4 million in 2022, then decreased by 7.21% to $295.5 million in 2023, then soared by 109.6% to $619.4 million in 2024, then fell by 2.03% to $606.8 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Current Assets are $606.8 million (Q4 2025), $440.6 million (Q3 2025), and $515.3 million (Q2 2025).